Literature DB >> 11498739

Kinetics of standardized large volume leukapheresis (LVL) in patients do not show a recruitment phenomenon of peripheral blood progenitor cells (PBPC).

U Cassens1, P H Momkvist, M Zuehlsdorf, M Mohr, J Kienast, W E Berdel, W Sibrowski.   

Abstract

Although several studies have demonstrated the efficacy of large volume leukapheresis (LVL) to yield high numbers of peripheral blood progenitor cells (PBPC), the mechanisms of stem cell release into circulation and the postulated phenomenon of PBPC recruitment during apheresis have not been investigated in detail. Therefore, we analyzed the kinetics of stem cell enrichment in a total of 34 standardized LVL for patients with hematologic malignancies (lymphoma, multiple myeloma) and solid tumors (breast cancer, rhabdomyosarcoma). LVL was started 2 h after administration of G-CSF processing six times the patient's blood volume. Cells were sequentially collected into six bags and the numbers of leukocytes, mononuclear cells (MNC), CD34+ cells and colony-forming cells (CFU-GM) in each collection bag were analyzed. The numbers of PBPC collected demonstrated a continuous decrease starting after an early maximum during the second processed blood volume (P = 0.001). Interestingly, these kinetics of decreasing stem cell yields during LVL were similar for both entities of patients with hematologic malignancies as well as for both groups of patients with solid tumors. In summary, a recruitment phenomenon, defined as a time-dependent and LVL-induced increase of PBPC, could not be demonstrated in any of the diseases investigated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11498739     DOI: 10.1038/sj.bmt.1703082

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  3 in total

1.  A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation.

Authors:  Heather Renfroe; Mike Arnold; Louette Vaughn; R Donald Harvey; Ellie Hamilton; Sagar Lonial; H Jean Khoury; Jonathan L Kaufman; Mary Jo Lechowicz; Christopher R Flowers; Edmund K Waller
Journal:  Transfusion       Date:  2011-02-18       Impact factor: 3.157

2.  Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.

Authors:  Nigel Russell; Kenny Douglas; Anthony D Ho; Mohamad Mohty; Kristina Carlson; G J Ossenkoppele; Giuseppe Milone; Macarena Ortiz Pareja; Daniel Shaheen; Arnold Willemsen; Nicky Whitaker; Christian Chabannon
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

3.  Harvesting, processing and inventory management of peripheral blood stem cells.

Authors:  Aleksandar Mijovic; Derwood Pamphilon
Journal:  Asian J Transfus Sci       Date:  2007-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.